Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer Interventions: Drug: CA102N; Drug: TAS-102; Biological: Bevacizumab Sponsor: Holy Stone Healthcare Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Conditions: Hemorrhagic Hereditary Telangiectasia; HHT Intervention: Other: bevacizumab treatment Sponsor: Hospices Civils de Lyon Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer Interventions: Drug: CA102N; Drug: TAS-102; Biological: Bevacizumab Sponsor: Holy Stone Healthcare Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Conditions: Hemorrhagic Hereditary Telangiectasia; HHT Intervention: Other: bevacizumab treatment Sponsor: Hospices Civils de Lyon Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Conditions: Hemorrhagic Hereditary Telangiectasia; HHT Intervention: Other: bevacizumab treatment Sponsor: Hospices Civils de Lyon Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer Interventions: Drug: CA102N; Drug: TAS-102; Biological: Bevacizumab Sponsor: Holy Stone Healthcare Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
Condition: Hepatocellular Carcinoma (HCC) Interventions: Drug: Durvalumab; Drug: Bevacizumab; Procedure: Transarterial Radioembolization (TARE) Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer Interventions: Drug: CA102N; Drug: TAS-102; Biological: Bevacizumab Sponsor: Holy Stone Healthcare Co., Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 15, 2023 Category: Research Source Type: clinical trials
